TY - JOUR
T1 - Characterization of a gain of function mutation of integrin αIIbβ3 (platelet glycoprotein IIb-IIIa)
AU - Bajt, Mary Lynn
AU - Loftus, Joseph C.
AU - Gawaz, Meinrad P.
AU - Ginsberg, Mark H.
N1 - Copyright:
Copyright 2004 Elsevier B.V., All rights reserved.
PY - 1992/11/5
Y1 - 1992/11/5
N2 - Integrin αIIbβ3 (platelet glycoprotein IIb-IIIa) is a prototype of integrins involved in cellular adhesive functions. As part of a structure-function analysis of this molecule, we constructed a mutant, designated αIIbβ3(β1-2), by replacing 6 amino acids within a putative ligand binding domain of the β3 subunit with sequences derived from β1. The alteration did not affect the capacity of β3(β1-2) to combine with transfected αIIb, nor did it cause it to combine with endogenous α5. Integrin αIIbβ3(β1-2) was in a "resting" state on Chinese hamster ovary cells as judged by minimal binding of an activation-specific anti-αIIbβ3, PAC1. Nevertheless, cells expressing αIIbβ3(β1-2) spontaneously bound fibrinogen with low affinity (Kα = (4.85 ± 0.84) × 106 M-1). Activation with an anti-β3 antibody (monoclonal antibody 62) resulted in a 10-fold increase in fibrinogen binding affinity (Kα = (4.55 ± 0.77) × 107 M-1), which was 3-fold greater than fibrinogen binding to activated wild type αIIbβ3 (Kα = (1.66 ± 0.33) × 107 M-1, F= 7.46, p = 0.008). The mutant receptor also bound fibrinogen mimetic peptide ligands with enhanced affinity as measured by the conformation-specific antibody, anti-LIBS1. This indicates that the increased affinity for fibrinogen was caused by enhanced interaction of αIIbβ3(β1-2) with known recognition sequences in fibrinogen. Thus, this gain of function mutant augments ligand binding function, supporting a role for this region of the β subunit in ligand binding to integrins.
AB - Integrin αIIbβ3 (platelet glycoprotein IIb-IIIa) is a prototype of integrins involved in cellular adhesive functions. As part of a structure-function analysis of this molecule, we constructed a mutant, designated αIIbβ3(β1-2), by replacing 6 amino acids within a putative ligand binding domain of the β3 subunit with sequences derived from β1. The alteration did not affect the capacity of β3(β1-2) to combine with transfected αIIb, nor did it cause it to combine with endogenous α5. Integrin αIIbβ3(β1-2) was in a "resting" state on Chinese hamster ovary cells as judged by minimal binding of an activation-specific anti-αIIbβ3, PAC1. Nevertheless, cells expressing αIIbβ3(β1-2) spontaneously bound fibrinogen with low affinity (Kα = (4.85 ± 0.84) × 106 M-1). Activation with an anti-β3 antibody (monoclonal antibody 62) resulted in a 10-fold increase in fibrinogen binding affinity (Kα = (4.55 ± 0.77) × 107 M-1), which was 3-fold greater than fibrinogen binding to activated wild type αIIbβ3 (Kα = (1.66 ± 0.33) × 107 M-1, F= 7.46, p = 0.008). The mutant receptor also bound fibrinogen mimetic peptide ligands with enhanced affinity as measured by the conformation-specific antibody, anti-LIBS1. This indicates that the increased affinity for fibrinogen was caused by enhanced interaction of αIIbβ3(β1-2) with known recognition sequences in fibrinogen. Thus, this gain of function mutant augments ligand binding function, supporting a role for this region of the β subunit in ligand binding to integrins.
UR - http://www.scopus.com/inward/record.url?scp=0026564426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026564426&partnerID=8YFLogxK
M3 - Article
C2 - 1429573
AN - SCOPUS:0026564426
SN - 0021-9258
VL - 267
SP - 22211
EP - 22216
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 31
ER -